Effects of ulinastatin treatment on myocardial and renal injury in patients undergoing aortic valve replacement with cardiopulmonary bypass

Korean Journal of Anesthesiology 2012년 62권 2호 p.148 ~ p.153

오세용(Oh Se-Young) - Yonsei University College of Medicine Department of Anesthesiology and Pain Medicine
김종찬(Kim Jong-Chan) - Kyungpook National University Hospital Department of Anesthesiology and Pain Medicine
최용선(Choi Yong-Seon) - Yonsei University College of Medicine Department of Anesthesiology and Pain Medicine
이우경(Lee Woo-Kyung) - Yonsei University College of Medicine Department of Anesthesiology and Pain Medicine
이영규(Lee Yeong-Kyu) - Yonsei University College of Medicine Department of Anesthesiology and Pain Medicine
곽영란(Kwak Young-Lan) - Yonsei University College of Medicine Department of Anesthesiology and Pain Medicine

Abstract

Background: We determined the protective effects of a high dose of ulinastatin on myocardial and renal function in patients undergoing aortic valve replacement with cardiopulmonary bypass (CPB).

Methods: Sixty patients were assigned randomly to either the ulinastatin group (n = 30) or the control group (n = 30). In the ulinastatin group, ulinastatin (300,000 U) was given after the induction of anesthesia, ulinastatin (400,000 U) was added to the CPB pump prime, and then ulinastatin (300,000 U) was administered after weaning from CPB. In the control group, the same volume of saline was administered at the same time points. Creatine kinase-MB levels were assessed 1 day before surgery, and on the first and second postoperative day (POD 1 and 2). Serum creatinine and cystatin C levels were assessed 1 day before surgery, upon intensive care unit arrival, and on POD 1 and 2. The level of plasma neutrophil gelatinase-associated lipocalin was assessed before induction of anesthesia, upon ICU arrival, and on POD 1.

Results: No significant differences were observed in serum levels of creatine kinase-MB and biomarkers of renal injury between the two groups at any point during the study period.

Conclusions: Ulinastatin showed no cardiac or renal protective effects after CPB in patients undergoing aortic valve replacement.

키워드

Cardiac surgical procedures, Cardiopulmonary bypass, Myocardiac protection
원문 및 링크아웃 정보
등재저널 정보
MEDLINE 학술진흥재단(KCI) KoreaMed 대한의학회 회원 
주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
ulinastatin did not effectively reduce CBP-induced damage to the heart and kidneys of patients who underwent an aortic valve replacement. No significant differences in serum levels of CK-MB, creatinine, cystatin C, or NGAL were observed between the groups throughout the study period.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
KCD코드
ICD 03
건강보험코드